Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 1998, p. 1146-1150, Vol. 42, No. 5
Division of Biopharmaceutics,
Received 10 July 1997/Returned for modification 14 October
1997/Accepted 10 February 1998
The acyclic nucleoside phosphonate
(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine
[(S)-HPMPA] has been shown to be active against
pathogens, like hepatitis B viruses and Plasmodium
parasites, that infect parenchymal liver cells. (S)-HPMPA
is therefore an interesting candidate drug for the treatment of these
infections. To establish effective therapeutic protocols for
(S)-HPMPA, it is essential that the kinetics of its hepatic
uptake be evaluated and that the role of the various liver cell types
be examined. In the present study, we investigated the disposition of
(S)-HPMPA and assessed its hepatic uptake. Rats were
intravenously injected with [3H](S)-HPMPA,
and after an initial rapid distribution phase (360 ± 53 ml/kg of
body weight), the radioactivity was cleared from the circulation with a
half-life of 11.7 ± 1.4 min. The tissue distribution of
[3H](S)-HPMPA was determined at 90 min after
injection (when >99% of the dose cleared). Most (57.0% ± 1.1%) of
the injected [3H](S)-HPMPA was excreted
unchanged in the urine. The radioactivity that was retained in the body
was almost completely recovered in the kidneys and the liver (68.4% ± 2.5% and 16.1% ± 0.4% of the radioactivity in the body,
respectively). The uptake of [3H](S)-HPMPA by
the liver occurred mainly by parenchymal cells (92.1% ± 3.4% of
total uptake by the liver). Kupffer cells and endothelial cells
accounted for only 6.1% ± 3.5% and 1.8% ± 0.8% of the total
uptake by the liver, respectively. Preinjection with probenecid reduced
the hepatic and renal uptake of [3H](S)-HPMPA
by approximately 75%, which points to a major role of a
probenecid-sensitive transporter in the uptake of (S)-HPMPA by both tissues. In conclusion, we show that inside the liver, (S)-HPMPA is mainly taken up by parenchymal liver cells.
However, the level of uptake by the kidneys is much higher, which leads to nephrotoxicity. An approach in which (S)-HPMPA is
coupled to carriers that are specifically taken up by parenchymal cells
may increase the effectiveness of the drug in the liver and reduce its
renal toxicity.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Disposition of the Acyclic Nucleoside Phosphonate
(S)-9(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine
*
Corresponding author. Mailing address: Division of
Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, P.O. Box
9503, 2300 RA Leiden, The Netherlands. Phone: 31-71-5276038. Fax:
31-71-5276032. E-mail: BIJSTERB{at}CHEM.LEIDENUNIV.NL.
Antimicrobial Agents and Chemotherapy, May 1998, p. 1146-1150, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»